Effects of intravenous pamidronate on renal function, bone mineral metabolism and bone mass in patients with severe osteoporosis

American Journal of the Medical Sciences

Volumn 339, Issue 3, 2010, Pages 225-229

  Hernandez, M Victoria ^a   Peris, Pilar ^a,b   Monegal, Ana ^a   Reyes, Raquel ^a   Muxi, Africa ^a   Gifre, Laia ^a   Guañabens, Nuria ^a,b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Bisphosphonates; Bone markers; Bone mineral density; Fractures; Kidney

Indexed keywords

25 HYDROXYVITAMIN D; AMINO TERMINAL PROPEPTIDE OF TYPE 1 PROCOLLAGEN; AMINO TERMINAL TELOPEPTIDE; CALCIUM; COLLAGEN; CREATININE; DIPHENHYDRAMINE; METHYLPREDNISOLONE; PAMIDRONIC ACID; PARATHYROID HORMONE; PHOSPHATE; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; BONE REMODELING; BONE TURNOVER; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; HUMAN; INJECTION SITE DYSPNEA; INJECTION SITE PRURITUS; INJECTION SITE REACTION; KIDNEY FUNCTION; MALE; OSTEOPOROSIS; VERTEBRA FRACTURE;

EID: 77949467459     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181c7c89c     Document Type: Article

References (27)

1. Iwamoto J, Takeda T, Sato Y. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Curr Med Res Opin 2006;22:919-928
2. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-2082
3. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282:1344-1352
4. Ettinger B, Pressman A, Schein J, et al. Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Managed Care Pharm 1998; 4:488-491
5. De Groen P, Lubbe D, Hirsch L, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-1021
6. Wellington K, Goa KL. Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy. Drugs 2003;63:417-437
7. Coukell AJ, Markham A. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone. Drugs Aging 1998;12:149-168
8. Reid IR, Miller P, Lyles K, et al. A single infusion of zoledronic acid improves remission rates in Paget's disease: a randomized controlled comparison with risedronate. N Engl J Med 2005;353:898-908.
9. Peretz A, Body JJ, Dumon JC, et al. Cyclical pamidronate infusions in postmenopausal osteoporosis. Maturitas 1996;25:69-75.
10. Boutsen Y, Jamart J, Esselinckx W, et al. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res 2001;16:104-112
11. Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int 2008;74:1385-1393
12. WHO Technical Report Series 843: Assessment of fracture risk and its applications to screening for postmenopausal osteoporosis. World Health Organization, Geneva, 1994.
13. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992;38: 1933-1953
14. Genant HK, Jergas M, Palermo L, et al. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fracture in osteoporosis. J Bone Miner Res 1996;11:984-996
15. Cauza E, Etemad M, Winkler F, et al. Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis. J Clin Pharm Ther 2004;29:431-436
16. Heijckmann AC, Juttmann JR, Wolffenbuttel BH. Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis. Neth J Med 2002;60:315-319
17. Chan SS, Nery LM, McElduff A, et al. Intravenous pamidronate in the treatment and prevention of osteoporosis. Intern Med J 2004;34: 162-166
18. Miller RG, Chretien KC, Meoni LA, et al. Comparison of intravenous pamidronate to standard therapy for osteoporosis: use in patients unable to take oral bisphosphonates. J Clin Rheumatol 2005;11:2-7.
19. Pennisi P, Trombetti A, Giostra E, et al. Pamidronate and osteoporosis prevention in liver transplant recipients. Rheumatol Int 2007;27: 251-256
20. Monegal A, Guañabens N, Suárez MJ, et al. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial. Transpl Int 2009;22:198-206.
21. Trombetti A, Gerbase MW, Spiliopoulos A, et al. Bone mineral density in lung-transplant recipients before and after graft: prevention of lumbar spine post-transplantation-accelerated bone loss by pamidronate. J Heart Lung Transplant 2000;19:736-743
22. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-1441
23. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-323
24. Díez-Pérez A, González-Macías J. Inadequate responders to osteoporosis treatment: proposal for an operational definition. Osteoporos Int 2008;19:1511-1516
25. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006;17: 897-907.
26. Oh WK, Proctor K, Nakabayashi M, et al. The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer 2007;109:1090-1096
27. Nagahama M, Sica DA. Pamidronate-induced injury in a patient with metastatic breast cancer. Am J Med Sci 2009;338:225-228